\
&
Contact us
\
&
Contact us
Starts in 6 days from now
LocationHybrid + Brussels
The European Commission’s flagship research and innovation event aims to bring together policymakers, researchers, innovators, business leaders and representatives of civil society. It is designed to look at how research and innovation can strengthen Europe’s competitiveness, resilience and technological sovereignty. The programme is expected to include high-level policy discussions, breakout sessions, networking opportunities, award ceremonies and exchanges with EU Science Counsellors.
The seventh edition of the European Research & Innovation days will cover topics such as freedom of scientific research, support for research talent, investment in research and development, technological leadership, support for innovative companies, research and technology infrastructures, international cooperation, citizen engagement with science, and better alignment of European and national research policies and investments.
Across two days, participants will be able to join policy debates, interactive sessions and networking activities. President Urusula Von Der Leyen will kick-start the event, with opening remarks from Commissioner Ekaterina Zaharieva.
On-site participation is not possible anymore but online live streaming will be available.
All information, including the programme and live streaming, is available on the event page.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
